KOTAI Biotechnologies Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7.1M

KOTAI Biotechnologies General Information

Description

Developer of a structural modeling and analysis platform for immune cell receptors designed to aid in better drug discovery. The company leverages algorithms and data to reveal the structure and function of immune cell receptors from blood to help in better diagnosis, prognosis, and drug efficacy prediction, enabling pharmaceutical companies to bring efficacy to drug discovery.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 2nd Floor, Building B, Office For Industry-University Co-Creation
  • Osaka University, 2-1 Yamadaoka, Suita
  • Osaka, 565-0871
  • Japan
+81
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Other Healthcare Technology Systems
Parent Company
Vertical(s)
LOHAS & Wellness, HealthTech
Corporate Office
  • 2nd Floor, Building B, Office For Industry-University Co-Creation
  • Osaka University, 2-1 Yamadaoka, Suita
  • Osaka, 565-0871
  • Japan
+81

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KOTAI Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 31-Jul-2023 $7.1M Completed Generating Revenue
3. Later Stage VC (Series C) 28-Oct-2020 Completed Generating Revenue
2. Early Stage VC (Series B) 28-Aug-2017 $1.83M $2.32M Completed Startup
1. Early Stage VC (Series A) 21-Oct-2016 $487K $487K Completed Startup
To view KOTAI Biotechnologies’s complete valuation and funding history, request access »

KOTAI Biotechnologies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C preferred
B preferred
A preferred 2,500 $189.86 $189.86 1x $189.86 7.37%
To view KOTAI Biotechnologies’s complete cap table history, request access »

KOTAI Biotechnologies Patents

KOTAI Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022187385-A Antibodies against sars-cov-2 spike protein Pending 07-Jun-2021
EP-4310171-A1 Novel medical technique using follicular t-cells Pending 16-Mar-2021
EP-4310095-A1 Follicular helper t (tfh) cells specific to sars-cov-2 virus Pending 16-Mar-2021
US-20240159738-A1 Novel medical technique using follicular t-cells Pending 16-Mar-2021
US-20240309051-A1 Follicular helper t (tfh) cells specific to sars-cov-2 virus Pending 16-Mar-2021 A61K39/12
To view KOTAI Biotechnologies’s complete patent history, request access »

KOTAI Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KOTAI Biotechnologies Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amashin-Shinkin Venture Capital Minority
Japan Agency for Medical Research and Development Government Minority
Minato Growing Enterprises Venture Capital Minority
New Energy and Industrial Technology Development Organization Government Minority
Nippon Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

KOTAI Biotechnologies FAQs

  • When was KOTAI Biotechnologies founded?

    KOTAI Biotechnologies was founded in 2016.

  • Where is KOTAI Biotechnologies headquartered?

    KOTAI Biotechnologies is headquartered in Osaka, Japan.

  • What is the size of KOTAI Biotechnologies?

    KOTAI Biotechnologies has 20 total employees.

  • What industry is KOTAI Biotechnologies in?

    KOTAI Biotechnologies’s primary industry is Biotechnology.

  • Is KOTAI Biotechnologies a private or public company?

    KOTAI Biotechnologies is a Private company.

  • What is the current valuation of KOTAI Biotechnologies?

    The current valuation of KOTAI Biotechnologies is .

  • What is KOTAI Biotechnologies’s current revenue?

    The current revenue for KOTAI Biotechnologies is .

  • How much funding has KOTAI Biotechnologies raised over time?

    KOTAI Biotechnologies has raised $4.79M.

  • Who are KOTAI Biotechnologies’s investors?

    Amashin-Shinkin, Japan Agency for Medical Research and Development, Minato Growing Enterprises, New Energy and Industrial Technology Development Organization, and Nippon Venture Capital are 5 of 8 investors who have invested in KOTAI Biotechnologies.

  • When was KOTAI Biotechnologies acquired?

    KOTAI Biotechnologies was acquired on 31-Jul-2023.

  • Who acquired KOTAI Biotechnologies?

    KOTAI Biotechnologies was acquired by Sanyo Trading Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »